We seek a highly motivated and self-directed individual to develop Merrimack’s novel pipeline of human therapeutic antibodies. This is an exciting opportunity to have a real impact first in furthering Cancer Patient care with novel drugs and also on the future success of the company.

This individual will oversee the direction, planning, execution, and interpretation of clinical trials/research and the data collection activities and work closely with cross-functional project teams to provide strategic and tactical clinical expertise for these projects.

Responsibilities will include designing and executing oncology clinical trials in close collaboration with scientists, clinical operations and regulatory professionals at Merrimack and with staff at CROs. He/she will assist in preparing the clinical portions of regulatory documents to support the program including protocols, investigator brochures, medical reports, efficacy and safety summaries and background information. The Medical Director will also be working directly with outside clinical investigators and oncology thought leaders.
 

The Projects: MM-121 & MM-111

You will be working on one of two projects. The first, MM-121, is Merrimack’s lead candidate, is a fully human monoclonal antibody that targets the ErbB3 receptor. MM-121 is the first selective ErbB3 antagonist to enter human clinical development. Merrimack recently entered into a worldwide development agreement with Sanofi-Aventis for MM-121. The second project, MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression or amplification of ErbB2 (HER2). Both projects are in Phase I/II human trials.